FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377016714> ?p ?o ?g. }

• W4377016714 endingPage "102004" @default.
• W4377016714 startingPage "102004" @default.
• W4377016714 abstract "BackgroundCOVID-19 progression is associated with an increased risk of arterial and venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the risk of thromboembolism in hospitalised patients with COVID-19, but a benefit of routine anticoagulation has not been demonstrated in the outpatient setting.MethodsWe conducted a randomised, open-label, controlled, multicentre study, evaluating the use of rivaroxaban in mild or moderate COVID-19 patients. Adults ≥18 years old, with probable or confirmed SARS-CoV-2 infection, presenting within ≤7 days from symptom onset with no clear indication for hospitalization, plus at least 2 risk factors for complication, were randomised 1:1 either to rivaroxaban 10 mg OD for 14 days or to routine care. The primary efficacy endpoint was the composite of venous thromboembolic events, need of mechanical ventilation, acute myocardial infarction, stroke, acute limb ischemia, or death due to COVID-19 during the first 30 days. ClinicalTrials.gov: NCT04757857.FindingsEnrollment was prematurely stopped due to sustained reduction in new COVID-19 cases. From September 29th, 2020, through May 23rd, 2022, 660 patients were randomised (median age 61 [Q1-Q3 47–69], 55.7% women). There was no significant difference between rivaroxaban and control in the primary efficacy endpoint (4.3% [14/327] vs 5.8% [19/330], RR 0.74; 95% CI: 0.38–1.46). There was no major bleeding in the control group and 1 in the rivaroxaban group.InterpretationOn light of these findings no decision can be made about the utility of rivaroxaban to improve outcomes in outpatients with COVID-19. Metanalyses data provide no evidence of a benefit of anticoagulant prophylaxis in outpatients with COVID-19. These findings were the result of an underpowered study, therefore should be interpreted with caution.FundingCOALITION COVID-19 Brazil and Bayer S.A. COVID-19 progression is associated with an increased risk of arterial and venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the risk of thromboembolism in hospitalised patients with COVID-19, but a benefit of routine anticoagulation has not been demonstrated in the outpatient setting. We conducted a randomised, open-label, controlled, multicentre study, evaluating the use of rivaroxaban in mild or moderate COVID-19 patients. Adults ≥18 years old, with probable or confirmed SARS-CoV-2 infection, presenting within ≤7 days from symptom onset with no clear indication for hospitalization, plus at least 2 risk factors for complication, were randomised 1:1 either to rivaroxaban 10 mg OD for 14 days or to routine care. The primary efficacy endpoint was the composite of venous thromboembolic events, need of mechanical ventilation, acute myocardial infarction, stroke, acute limb ischemia, or death due to COVID-19 during the first 30 days. ClinicalTrials.gov: NCT04757857. Enrollment was prematurely stopped due to sustained reduction in new COVID-19 cases. From September 29th, 2020, through May 23rd, 2022, 660 patients were randomised (median age 61 [Q1-Q3 47–69], 55.7% women). There was no significant difference between rivaroxaban and control in the primary efficacy endpoint (4.3% [14/327] vs 5.8% [19/330], RR 0.74; 95% CI: 0.38–1.46). There was no major bleeding in the control group and 1 in the rivaroxaban group. On light of these findings no decision can be made about the utility of rivaroxaban to improve outcomes in outpatients with COVID-19. Metanalyses data provide no evidence of a benefit of anticoagulant prophylaxis in outpatients with COVID-19. These findings were the result of an underpowered study, therefore should be interpreted with caution." @default.
• W4377016714 created "2023-05-19" @default.
• W4377016714 creator A5007066148 @default.
• W4377016714 creator A5007820479 @default.
• W4377016714 creator A5010734379 @default.
• W4377016714 creator A5012717117 @default.
• W4377016714 creator A5016024795 @default.
• W4377016714 creator A5024069660 @default.
• W4377016714 creator A5026624366 @default.
• W4377016714 creator A5026937673 @default.
• W4377016714 creator A5028640370 @default.
• W4377016714 creator A5031342838 @default.
• W4377016714 creator A5031354505 @default.
• W4377016714 creator A5035924423 @default.
• W4377016714 creator A5036737750 @default.
• W4377016714 creator A5038564675 @default.
• W4377016714 creator A5043669328 @default.
• W4377016714 creator A5043904209 @default.
• W4377016714 creator A5045428125 @default.
• W4377016714 creator A5048325645 @default.
• W4377016714 creator A5048589872 @default.
• W4377016714 creator A5052875900 @default.
• W4377016714 creator A5053538215 @default.
• W4377016714 creator A5064463586 @default.
• W4377016714 creator A5066324526 @default.
• W4377016714 creator A5067237537 @default.
• W4377016714 creator A5075702354 @default.
• W4377016714 creator A5084746877 @default.
• W4377016714 creator A5086287744 @default.
• W4377016714 creator A5086718316 @default.
• W4377016714 creator A5086979902 @default.
• W4377016714 creator A5090147070 @default.
• W4377016714 date "2023-06-01" @default.
• W4377016714 modified "2023-09-27" @default.
• W4377016714 title "Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trial" @default.
• W4377016714 cites W1938916414 @default.
• W4377016714 cites W2105084079 @default.
• W4377016714 cites W2108696783 @default.
• W4377016714 cites W2162499932 @default.
• W4377016714 cites W2888169160 @default.
• W4377016714 cites W2944434778 @default.
• W4377016714 cites W3016126001 @default.
• W4377016714 cites W3082092786 @default.
• W4377016714 cites W3089167000 @default.
• W4377016714 cites W3136016654 @default.
• W4377016714 cites W3197892791 @default.
• W4377016714 cites W3200339764 @default.
• W4377016714 cites W3205387447 @default.
• W4377016714 cites W3206483794 @default.
• W4377016714 cites W4205922819 @default.
• W4377016714 cites W4231969161 @default.
• W4377016714 cites W4284709425 @default.
• W4377016714 cites W4284882030 @default.
• W4377016714 cites W4289433284 @default.
• W4377016714 cites W4317107833 @default.
• W4377016714 cites W4328088940 @default.
• W4377016714 doi "https://doi.org/10.1016/j.eclinm.2023.102004" @default.
• W4377016714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37223666" @default.
• W4377016714 hasPublicationYear "2023" @default.
• W4377016714 type Work @default.
• W4377016714 citedByCount "0" @default.
• W4377016714 crossrefType "journal-article" @default.
• W4377016714 hasAuthorship W4377016714A5007066148 @default.
• W4377016714 hasAuthorship W4377016714A5007820479 @default.
• W4377016714 hasAuthorship W4377016714A5010734379 @default.
• W4377016714 hasAuthorship W4377016714A5012717117 @default.
• W4377016714 hasAuthorship W4377016714A5016024795 @default.
• W4377016714 hasAuthorship W4377016714A5024069660 @default.
• W4377016714 hasAuthorship W4377016714A5026624366 @default.
• W4377016714 hasAuthorship W4377016714A5026937673 @default.
• W4377016714 hasAuthorship W4377016714A5028640370 @default.
• W4377016714 hasAuthorship W4377016714A5031342838 @default.
• W4377016714 hasAuthorship W4377016714A5031354505 @default.
• W4377016714 hasAuthorship W4377016714A5035924423 @default.
• W4377016714 hasAuthorship W4377016714A5036737750 @default.
• W4377016714 hasAuthorship W4377016714A5038564675 @default.
• W4377016714 hasAuthorship W4377016714A5043669328 @default.
• W4377016714 hasAuthorship W4377016714A5043904209 @default.
• W4377016714 hasAuthorship W4377016714A5045428125 @default.
• W4377016714 hasAuthorship W4377016714A5048325645 @default.
• W4377016714 hasAuthorship W4377016714A5048589872 @default.
• W4377016714 hasAuthorship W4377016714A5052875900 @default.
• W4377016714 hasAuthorship W4377016714A5053538215 @default.
• W4377016714 hasAuthorship W4377016714A5064463586 @default.
• W4377016714 hasAuthorship W4377016714A5066324526 @default.
• W4377016714 hasAuthorship W4377016714A5067237537 @default.
• W4377016714 hasAuthorship W4377016714A5075702354 @default.
• W4377016714 hasAuthorship W4377016714A5084746877 @default.
• W4377016714 hasAuthorship W4377016714A5086287744 @default.
• W4377016714 hasAuthorship W4377016714A5086718316 @default.
• W4377016714 hasAuthorship W4377016714A5086979902 @default.
• W4377016714 hasAuthorship W4377016714A5090147070 @default.
• W4377016714 hasBestOaLocation W43770167141 @default.
• W4377016714 hasConcept C126322002 @default.
• W4377016714 hasConcept C127413603 @default.
• W4377016714 hasConcept C168563851 @default.
• W4377016714 hasConcept C194828623 @default.
• W4377016714 hasConcept C202953159 @default.

• next